Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,128 public posts
Filter results
Inhibition of Cancer Stem Cells Promoted by Pimozide.
From 2017 [3]: "Mechanisms of
castration
-resistant prostate cancer (CRPC) are not well understood, thus hindering rational-based drug design. Activation of STAT3/5A, key components of the JAK/STAT pathway, is implicated in aggressive PC, yet their clinical relevance in CRPC remains elusive.
From 2017 [3]: "Mechanisms of
castration
-resistant prostate cancer (CRPC) are not well understood, thus hindering rational-based drug design. Activation of STAT3/5A, key components of the JAK/STAT pathway, is implicated in aggressive PC, yet their clinical relevance in CRPC remains elusive.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Androgen Annihilation.
Huggins simply hadn't gone far enough with
castration
. What was needed was a scorched earth approach (& hopefully the cure wouldn't kill the patient). 'Androgen Annihilation' is self-explanatory. It means total war on the AR. & it implies using multiple drugs - one for each escape route.
Huggins simply hadn't gone far enough with
castration
. What was needed was a scorched earth approach (& hopefully the cure wouldn't kill the patient). 'Androgen Annihilation' is self-explanatory. It means total war on the AR. & it implies using multiple drugs - one for each escape route.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Xtandi [Enzalutamide ]. Continuation of ADT after CRPC & chemo.
[Epub ahead of print] Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic
castration
-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data.
[Epub ahead of print] Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic
castration
-resistant prostate cancer following chemotherapy: results from retrospective, multicenter data.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
DHEA & Drug Resistance.
It is a precursor of intratumoral androgen biosynthesis in patients with advanced prostate cancer following chemical or surgical
castration
. DHEA is a product of the P450c17 (17α-hydroxylase-17,20-lyase) enzyme.
It is a precursor of intratumoral androgen biosynthesis in patients with advanced prostate cancer following chemical or surgical
castration
. DHEA is a product of the P450c17 (17α-hydroxylase-17,20-lyase) enzyme.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
HSD3B1 variant & Abiraterone (Zytiga).
Enabling of extragonadal DHT synthesis by HSD3B1(1245C) predicts for more rapid clinical resistance to
castration
and sensitivity to extragonadal androgen synthesis inhibition. HSD3B1(1245C) thus appears to define a subgroup of patients who benefit from blocking extragonadal androgens.
Enabling of extragonadal DHT synthesis by HSD3B1(1245C) predicts for more rapid clinical resistance to
castration
and sensitivity to extragonadal androgen synthesis inhibition. HSD3B1(1245C) thus appears to define a subgroup of patients who benefit from blocking extragonadal androgens.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Inhibition of estrogen signaling through depletion of estrogen receptor alpha by ursolic acid and betulinic acid from Prunella vulgaris var.
The ERβ is generally retained in hormone naïve and metastatic prostate cancer, but is partially lost in
castration
resistant disease. Prostate. 2018 Jan;78(1):2-10. doi: 10.1002/pros.23446. Epub 2017 Nov 2.
The ERβ is generally retained in hormone naïve and metastatic prostate cancer, but is partially lost in
castration
resistant disease. Prostate. 2018 Jan;78(1):2-10. doi: 10.1002/pros.23446. Epub 2017 Nov 2.
Kuanyin
in
Advanced Prostate Cancer
6 years ago
Progesterone Receptors in Prostate Cancer.
The trouble with Charles Huggins
castration
therapy of 1941, which looks as though it will be around in 2041, is that not only is it not a cure, but it has led to an obsession with the androgen receptor [AR].
The trouble with Charles Huggins
castration
therapy of 1941, which looks as though it will be around in 2041, is that not only is it not a cure, but it has led to an obsession with the androgen receptor [AR].
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Zytiga: "Phase II pilot study of the prednisone to dexamethasone switch ..."
"Despite most metastatic
castration
-resistant prostate cancer (mCRPC) patients benefit from abiraterone acetate plus prednisone 5 mg bid (AA + P), resistance eventually occurs.
"Despite most metastatic
castration
-resistant prostate cancer (mCRPC) patients benefit from abiraterone acetate plus prednisone 5 mg bid (AA + P), resistance eventually occurs.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Small-Cell PCa.
[Epub ahead of print] Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in
castration
-resistant prostate cancer metastases.
[Epub ahead of print] Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in
castration
-resistant prostate cancer metastases.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Help or Advice please
No reply, but
castration
was an option. I suspect there is more money to be made. I read in a post here that somebody had no side effects with Elegard. Any thoughts please.
No reply, but
castration
was an option. I suspect there is more money to be made. I read in a post here that somebody had no side effects with Elegard. Any thoughts please.
ARIES29
in
Advanced Prostate Cancer
6 years ago
Numerous bizarre genital symptoms after trazodone
- "Chemical
castration
", essentially no libido - numb genital, the testicles are almost completely numb the penis is only slightly better. The penis root feels numb and relaxed. It's like the connection separated between brain and penis. - The erections are not that strong anymore.
- "Chemical
castration
", essentially no libido - numb genital, the testicles are almost completely numb the penis is only slightly better. The penis root feels numb and relaxed. It's like the connection separated between brain and penis. - The erections are not that strong anymore.
Hidden
in
Pelvic Pain Support Network
6 years ago
Xtandi is approved for men with either metastatic or non-metastatic castration-resistant prostate cancer
The FDA ruling expands XTANDI use in men with metastatic
castration
-resistant prostate cancer (CRPC), in addition for men with non-metastatic
castration
-resistant prostate cancer. XTANDI is now the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.
The FDA ruling expands XTANDI use in men with metastatic
castration
-resistant prostate cancer (CRPC), in addition for men with non-metastatic
castration
-resistant prostate cancer. XTANDI is now the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.
Darryl
Partner
in
Advanced Prostate Cancer
6 years ago
Quo vadis?
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with
castration
-sensitive prostate cancer Abstract Purpose: Since the introduction of PSMA PET/CT with 68 Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide.
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with
castration
-sensitive prostate cancer Abstract Purpose: Since the introduction of PSMA PET/CT with 68 Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide.
Kuanyin
in
Advanced Prostate Cancer
6 years ago
Cholesterol biosynthesis & Enzalutamide resistance
Abstract Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved for the management of
castration
-resistant prostate cancer (CRPC).
Abstract Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved for the management of
castration
-resistant prostate cancer (CRPC).
pjoshea13
in
Advanced Prostate Cancer
6 years ago
An Update To My Profile And Entering A New Phase In My Journey
Brian This these are PBS requirement to receive Zytiga for $39.00 instead of $3,900.00
Castration
resistant metastatic carcinoma of the prostate Clinical criteria: The treatment must be used in combination with a corticosteroid, AND The treatment must not be used in combination with chemotherapy
Brian This these are PBS requirement to receive Zytiga for $39.00 instead of $3,900.00
Castration
resistant metastatic carcinoma of the prostate Clinical criteria: The treatment must be used in combination with a corticosteroid, AND The treatment must not be used in combination with chemotherapy
BrianE
in
Advanced Prostate Cancer
6 years ago
Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer
Here's the article I saw: https://www.ptcommunity.com/wire/status-update-phase-iii-aramis-clinical-trial-darolutamide-patients-non-metastatic-
castration
Here's the article I saw: https://www.ptcommunity.com/wire/status-update-phase-iii-aramis-clinical-trial-darolutamide-patients-non-metastatic-
castration
Hidden
in
Advanced Prostate Cancer
6 years ago
CellCentric raises $26 million to take first-in- class p300/CBP inhibitor into the clinic.
Looks promising, especially for our
castration
resistant brothers from the UK. http://www.cellcentric.com/press-releases/2018/may/15/cellcentric-raises-26-million-take-first-class-p30/ .
Looks promising, especially for our
castration
resistant brothers from the UK. http://www.cellcentric.com/press-releases/2018/may/15/cellcentric-raises-26-million-take-first-class-p30/ .
paulofaus
in
Advanced Prostate Cancer
6 years ago
Anti-aromatherapy?
They found that activating an olfactory receptor called OR51E2 in prostate cancer cells caused the cancer to morph into the more aggressive, ‘
castration
-resistant’ form of the disease.
They found that activating an olfactory receptor called OR51E2 in prostate cancer cells caused the cancer to morph into the more aggressive, ‘
castration
-resistant’ form of the disease.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Zenith Epigenetics Study Demonstrates Outstanding Results
("Zenith Epigenetics"), has initiated the Phase 2 portion of the ongoing metastatic
Castration
Resistant Prostate Cancer ("mCRPC") clinical trial in patients that have progressed on an androgen receptor antagonist (ARi).
("Zenith Epigenetics"), has initiated the Phase 2 portion of the ongoing metastatic
Castration
Resistant Prostate Cancer ("mCRPC") clinical trial in patients that have progressed on an androgen receptor antagonist (ARi).
Maxsayulita
in
Advanced Prostate Cancer
6 years ago
ASCO 2018 - Keytruda
If we can find out who will respond upfront, we may be able to avoid treatments such as
castration
for some patients," said de Bono. All is not lost for people who don't currently respond to immunotherapy alone though.
If we can find out who will respond upfront, we may be able to avoid treatments such as
castration
for some patients," said de Bono. All is not lost for people who don't currently respond to immunotherapy alone though.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
1
...
46
47
48
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1005 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest